XOMA (XOMA) Competitors $30.21 +0.33 (+1.10%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends XOMA vs. PGNX, CUE, OSMT, TXMD, NVAX, INVA, OPK, IRWD, EBS, and SGMOShould you be buying XOMA stock or one of its competitors? The main competitors of XOMA include Progenics Pharmaceuticals (PGNX), Cue Biopharma (CUE), Osmotica Pharmaceuticals (OSMT), TherapeuticsMD (TXMD), Novavax (NVAX), Innoviva (INVA), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), Emergent BioSolutions (EBS), and Sangamo Therapeutics (SGMO). These companies are all part of the "medical" sector. XOMA vs. Progenics Pharmaceuticals Cue Biopharma Osmotica Pharmaceuticals TherapeuticsMD Novavax Innoviva OPKO Health Ironwood Pharmaceuticals Emergent BioSolutions Sangamo Therapeutics Progenics Pharmaceuticals (NASDAQ:PGNX) and XOMA (NASDAQ:XOMA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability. Which has stronger valuation & earnings, PGNX or XOMA? XOMA has lower revenue, but higher earnings than Progenics Pharmaceuticals. XOMA is trading at a lower price-to-earnings ratio than Progenics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProgenics Pharmaceuticals$34.99M10.15-$68.55M-$0.80-5.13XOMA$4.76M74.76-$40.83M-$3.48-8.68 Do insiders and institutionals believe in PGNX or XOMA? 71.0% of Progenics Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.9% of XOMA shares are owned by institutional investors. 4.3% of Progenics Pharmaceuticals shares are owned by insiders. Comparatively, 7.2% of XOMA shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is PGNX or XOMA more profitable? XOMA has a net margin of -151.34% compared to Progenics Pharmaceuticals' net margin of -180.28%. XOMA's return on equity of -24.95% beat Progenics Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Progenics Pharmaceuticals-180.28% -129.46% -53.23% XOMA -151.34%-24.95%-9.64% Does the media prefer PGNX or XOMA? In the previous week, XOMA had 11 more articles in the media than Progenics Pharmaceuticals. MarketBeat recorded 11 mentions for XOMA and 0 mentions for Progenics Pharmaceuticals. XOMA's average media sentiment score of 0.79 beat Progenics Pharmaceuticals' score of 0.00 indicating that XOMA is being referred to more favorably in the news media. Company Overall Sentiment Progenics Pharmaceuticals Neutral XOMA Positive Does the MarketBeat Community prefer PGNX or XOMA? XOMA received 21 more outperform votes than Progenics Pharmaceuticals when rated by MarketBeat users. However, 68.66% of users gave Progenics Pharmaceuticals an outperform vote while only 66.11% of users gave XOMA an outperform vote. CompanyUnderperformOutperformProgenics PharmaceuticalsOutperform Votes41468.66% Underperform Votes18931.34% XOMAOutperform Votes43566.11% Underperform Votes22333.89% Which has more risk and volatility, PGNX or XOMA? Progenics Pharmaceuticals has a beta of 1.89, suggesting that its share price is 89% more volatile than the S&P 500. Comparatively, XOMA has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Do analysts rate PGNX or XOMA? XOMA has a consensus target price of $78.50, suggesting a potential upside of 159.85%. Given XOMA's stronger consensus rating and higher probable upside, analysts plainly believe XOMA is more favorable than Progenics Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Progenics Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00XOMA 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryXOMA beats Progenics Pharmaceuticals on 13 of the 18 factors compared between the two stocks. Ad Darwin2024's Must-Watch Stocks!Welcome to a year of unparalleled opportunities! Dive into our exclusive guide, "9 Stocks Set to Soar," meticulously selected to elevate your portfolio in 2024. Step into 2024 with confidence and the right assets at your fingertips. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time. [Unlock Your Report Now] Get XOMA News Delivered to You Automatically Sign up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XOMA vs. The Competition Export to ExcelMetricXOMAPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$355.87M$6.39B$5.07B$8.66BDividend YieldN/A8.04%5.09%4.06%P/E Ratio-8.6810.88101.9417.40Price / Sales74.76245.131,197.2969.07Price / CashN/A53.4940.9636.36Price / Book4.209.306.335.87Net Income-$40.83M$154.14M$119.64M$225.66M7 Day Performance-2.45%-9.47%-5.13%-1.34%1 Month Performance4.75%-7.29%-2.72%1.15%1 Year Performance89.17%28.20%31.06%24.02% XOMA Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XOMAXOMA4.4351 of 5 stars$30.21+1.1%$78.50+159.8%+104.1%$355.96M$4.76M-8.6810Insider SellingShort Interest ↓PGNXProgenics PharmaceuticalsN/A$4.10flatN/A+0.0%$355.05M$34.99M-5.3279Gap UpHigh Trading VolumeCUECue Biopharma4.4676 of 5 stars$1.64-3.5%N/A-47.7%$79.77M$5.49M-1.6960Short Interest ↓News CoverageOSMTOsmotica PharmaceuticalsN/AN/AN/AN/A$69.47M$177.88M-0.70302TXMDTherapeuticsMD0.7333 of 5 stars$1.48-1.3%N/A-40.4%$17.06M$1.30M0.00420Analyst ForecastShort Interest ↑News CoverageNVAXNovavax3.7314 of 5 stars$8.30-1.9%N/A+25.6%$1.33B$983.71M-3.671,543Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageINVAInnoviva1.35 of 5 stars$20.29-0.1%N/A+38.5%$1.27B$310.46M29.41112News CoverageOPKOPKO Health4.6578 of 5 stars$1.65+2.5%N/A+14.7%$1.13B$863.50M-8.683,930Insider BuyingIRWDIronwood Pharmaceuticals4.2073 of 5 stars$4.43+0.9%N/A-55.4%$707.65M$442.73M-147.67220Analyst DowngradeShort Interest ↓EBSEmergent BioSolutions4.4029 of 5 stars$10.27-5.7%N/A+264.2%$556.43M$1.05B-2.501,600Analyst UpgradeSGMOSangamo Therapeutics2.2761 of 5 stars$2.45-9.6%N/A+484.5%$510.14M$176.23M-3.27480Earnings ReportAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Progenics Pharmaceuticals Alternatives Cue Biopharma Alternatives Osmotica Pharmaceuticals Alternatives TherapeuticsMD Alternatives Novavax Alternatives Innoviva Alternatives OPKO Health Alternatives Ironwood Pharmaceuticals Alternatives Emergent BioSolutions Alternatives Sangamo Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:XOMA) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share XOMA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XOMA Stock Alerts